{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T05:59:34Z","timestamp":1787032774759,"version":"build-2736575974"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,28]]},"DOI":"10.7759\/cureus.100252","type":"journal-article","created":{"date-parts":[[2025,12,28]],"date-time":"2025-12-28T15:56:11Z","timestamp":1766937371000},"source":"Crossref","is-referenced-by-count":1,"title":["Impact of Glucagon-Like Peptide-1 Agonists on Hepatocellular Carcinoma Risk and Management in Type 2 Diabetes Mellitus: A Scoping Review"],"prefix":"10.7759","author":[{"given":"Bassam","family":"Tungekar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelyn C","family":"Echevarria Cruz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Dodrill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdul","family":"Muneeb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Sanderfoot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Thaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeet","family":"Vaishnav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arash","family":"Vahidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fadi","family":"Hindi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rayyan","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Nagy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin J","family":"Jacobs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01301-6","article-title":"Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021","volume":"402","year":"2023","unstructured":"Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050. a systematic analysis for the Global Burden of Disease Study 2021. Lancet. 2023, 402:203-34. 10.1016\/S0140-6736(23)01301-6","journal-title":"Lancet"},{"key":"ref2","unstructured":"Pathogenesis of type 2 diabetes mellitus. (2024). Accessed. March 18, 2025: https:\/\/www.uptodate.com\/contents\/pathogenesis-of-type-2-diabetes-mellitus."},{"key":"ref3","unstructured":"Initial management of hyperglycemia in adults with type 2 diabetes mellitus. (2025). Accessed. March 18, 2025: https:\/\/www.uptodate.com\/contents\/initial-management-of-hyperglycemia-in-adults-with-type-2-diabetes-mellitus."},{"key":"ref4","unstructured":"Compare and contrast the glucagon-like peptide-1 receptor agonists (GLP1RAs). (2024). Accessed. March 18, 2025: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK572151\/."},{"key":"ref5","unstructured":"GLP-1 agonist. (2023). Accessed. March 18, 2025: https:\/\/my.clevelandclinic.org\/health\/treatments\/13901-glp-1-agonists."},{"key":"ref6","unstructured":"Glucagon-like peptide 1-based therapies for the treatment of type 2 diabetes mellitus. (2024). Accessed. March 18, 2025: https:\/\/www.uptodate.com\/contents\/glucagon-like-peptide-1-based-therapies-for-the-treatment-of-type-2-diabetes-mellitus."},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.q1645","article-title":"GLP-1 agonists: US sees 700% increase over four years in number of patients without diabetes starting treatment","volume":"386","author":"Mahase E","year":"2024","unstructured":"Mahase E. GLP-1 agonists: US sees 700% increase over four years in number of patients without diabetes starting treatment. BMJ. 2024, 386:1645. 10.1136\/bmj.q1645","journal-title":"BMJ"},{"key":"ref8","unstructured":"Type 2 diabetes. (2023). Accessed. August 7, 2025: http:\/\/www.mayoclinic.org\/diseases-conditions\/type-2-diabetes\/symptomscauses\/syc-20351193."},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2023.2274536","article-title":"The role of glucagon-like peptide-1 receptor agonists in nonalcoholic fatty liver disease","volume":"16","author":"Tsiampali C","year":"2023","unstructured":"Tsiampali C, Papaioannidou P, Goulas A, Polyzos SA. The role of glucagon-like peptide-1 receptor agonists in nonalcoholic fatty liver disease. Expert Rev Clin Pharmacol. 2023, 16:1063-72. 10.1080\/17512433.2023.2274536","journal-title":"Expert Rev Clin Pharmacol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1186\/s40842-016-0027-7","article-title":"Treatment of nonalcoholic fatty liver disease (NAFLD) in patients with type 2 diabetes mellitus","volume":"2","author":"Portillo-Sanchez P","year":"2016","unstructured":"Portillo-Sanchez P, Cusi K. Treatment of nonalcoholic fatty liver disease (NAFLD) in patients with type 2 diabetes mellitus. Clin Diabetes Endocrinol. 2016, 2:9. 10.1186\/s40842-016-0027-7","journal-title":"Clin Diabetes Endocrinol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1002\/hep.32439","article-title":"Diabetes medications and risk of HCC","volume":"76","author":"Plaz Torres MC","year":"2022","unstructured":"Plaz Torres MC, Jaffe A, Perry R, Marabotto E, Strazzabosco M, Giannini EG. Diabetes medications and risk of HCC. Hepatology. 2022, 76:1880-97. 10.1002\/hep.32439","journal-title":"Hepatology"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1177\/08971900241253661","article-title":"Impact of GLP-1 receptor agonist use in patients with steatotic liver disease and type 2 diabetes: a retrospective cohort study","volume":"37","author":"Wood M","year":"2024","unstructured":"Wood M, Kennedy AG, Khan S, Hitt JR, Davis K, Reddy SS, Gilbert MP. Impact of GLP-1 receptor agonist use in patients with steatotic liver disease and type 2 diabetes: a retrospective cohort study. J Pharm Pract. 2024, 37:1297-302. 10.1177\/08971900241253661","journal-title":"J Pharm Pract"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12175597","article-title":"Nonalcoholic fatty liver disease in patients with type 2 diabetes: screening, diagnosis, and treatment","volume":"12","author":"Ciardullo S","year":"2023","unstructured":"Ciardullo S, Vergani M, Perseghin G. Nonalcoholic fatty liver disease in patients with type 2 diabetes: screening, diagnosis, and treatment. J Clin Med. 2023, 12:5597. 10.3390\/jcm12175597","journal-title":"J Clin Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2016.04.004","article-title":"Pharmacological management of nonalcoholic fatty liver disease","volume":"65","author":"Barb D","year":"2016","unstructured":"Barb D, Portillo-Sanchez P, Cusi K. Pharmacological management of nonalcoholic fatty liver disease. Metabolism. 2016, 65:1183-95. 10.1016\/j.metabol.2016.04.004","journal-title":"Metabolism"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1159\/000343852","article-title":"From cirrhosis to hepatocellular carcinoma: new molecular insights on inflammation and cellular senescence","volume":"2","author":"Ramakrishna G","year":"2013","unstructured":"Ramakrishna G, Rastogi A, Trehanpati N, Sen B, Khosla R, Sarin SK. From cirrhosis to hepatocellular carcinoma: new molecular insights on inflammation and cellular senescence. Liver Cancer. 2013, 2:367-83. 10.1159\/000343852","journal-title":"Liver Cancer"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3390\/ph11040121","article-title":"Antidiabetic drugs in NAFLD: the accomplishment of two goals at once?","volume":"11","author":"Tacelli M","year":"2018","unstructured":"Tacelli M, Celsa C, Magro B, Giannetti A, Pennisi G, Spatola F, Petta S. Antidiabetic drugs in NAFLD: the accomplishment of two goals at once?. Pharmaceuticals (Basel). 2018, 11:121. 10.3390\/ph11040121","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1111\/cts.12839","article-title":"Evolving role for pharmacotherapy in NAFLD\/NASH","volume":"14","author":"Attia SL","year":"2021","unstructured":"Attia SL, Softic S, Mouzaki M. Evolving role for pharmacotherapy in NAFLD\/NASH. Clin Transl Sci. 2021, 14:11-9. 10.1111\/cts.12839","journal-title":"Clin Transl Sci"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2024.111675","article-title":"Incretin-based investigational therapies for the treatment of MASLD\/MASH","volume":"211","author":"Brouwers B","year":"2024","unstructured":"Brouwers B, Rao G, Tang Y, Rodr\u00edguez \u00c1, Glass LC, Hartman ML. Incretin-based investigational therapies for the treatment of MASLD\/MASH. Diabetes Res Clin Pract. 2024, 211:111675. 10.1016\/j.diabres.2024.111675","journal-title":"Diabetes Res Clin Pract"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.2337\/dc21-1953","article-title":"Glucagon-like peptide 1 receptor agonists and sodium-glucose cotransporter 2 inhibitors and risk of nonalcoholic fatty liver disease among patients with type 2 diabetes","volume":"45","author":"Pradhan R","year":"2022","unstructured":"Pradhan R, Yin H, Yu O, Azoulay L. Glucagon-like peptide 1 receptor agonists and sodium-glucose cotransporter 2 inhibitors and risk of nonalcoholic fatty liver disease among patients with type 2 diabetes. Diabetes Care. 2022, 45:819-29. 10.2337\/dc21-1953","journal-title":"Diabetes Care"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2024.04.029","article-title":"Association of GLP-1 receptor agonists and hepatocellular carcinoma incidence and hepatic decompensation in patients with type 2 diabetes","volume":"167","author":"Wang L","year":"2024","unstructured":"Wang L, Berger NA, Kaelber DC, Xu R. Association of GLP-1 receptor agonists and hepatocellular carcinoma incidence and hepatic decompensation in patients with type 2 diabetes. Gastroenterology. 2024, 167:689-703. 10.1053\/j.gastro.2024.04.029","journal-title":"Gastroenterology"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.21305","article-title":"Glucagon-like peptide 1 receptor agonists and 13 obesity-associated cancers in patients with type 2 diabetes","volume":"7","author":"Wang L","year":"2024","unstructured":"Wang L, Xu R, Kaelber DC, Berger NA. Glucagon-like peptide 1 receptor agonists and 13 obesity-associated cancers in patients with type 2 diabetes. JAMA Netw Open. 2024, 7:2421305. 10.1001\/jamanetworkopen.2024.21305","journal-title":"JAMA Netw Open"},{"key":"ref22","unstructured":"IDF diabetes atlas. (2024). Accessed. August 19, 2025: http:\/\/diabetesatlas.org."},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000712","article-title":"Association of glucagon-like peptide-1 receptor agonists with serious liver events among patients with type 2 diabetes: a Scandinavian cohort study","volume":"79","author":"Engstr\u00f6m A","year":"2024","unstructured":"Engstr\u00f6m A, Wintzell V, Melbye M, et al.. Association of glucagon-like peptide-1 receptor agonists with serious liver events among patients with type 2 diabetes: a Scandinavian cohort study. Hepatology. 2024, 79:1401-11. 10.1097\/HEP.0000000000000712","journal-title":"Hepatology"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1111\/joim.13751","article-title":"Lower risks of cirrhosis and hepatocellular carcinoma with GLP-1RAs in type 2 diabetes: a nationwide cohort study using target trial emulation framework","volume":"295","author":"Yang CT","year":"2024","unstructured":"Yang CT, Yao WY, Yang CY, Peng ZY, Ou HT, Kuo S. Lower risks of cirrhosis and hepatocellular carcinoma with GLP-1RAs in type 2 diabetes: a nationwide cohort study using target trial emulation framework. J Intern Med. 2024, 295:357-68. 10.1111\/joim.13751","journal-title":"J Intern Med"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-023-03228-4","article-title":"Effects of glucagon-like peptide-1 receptor agonists on liver-related and cardiovascular mortality in patients with type 2 diabetes","volume":"22","author":"Yen FS","year":"2024","unstructured":"Yen FS, Hou MC, Wei JC, Shih YH, Hwu CM, Hsu CC. Effects of glucagon-like peptide-1 receptor agonists on liver-related and cardiovascular mortality in patients with type 2 diabetes. BMC Med. 2024, 22:8. 10.1186\/s12916-023-03228-4","journal-title":"BMC Med"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-024-02466-4","article-title":"Comparative outcomes of systemic diseases in people with type 2 diabetes, or obesity alone treated with and without GLP-1 receptor agonists: a retrospective cohort study from the Global Collaborative Network: author list","volume":"48","author":"Nassar M","year":"2025","unstructured":"Nassar M, Nassar O, Abosheaishaa H, Misra A. Comparative outcomes of systemic diseases in people with type 2 diabetes, or obesity alone treated with and without GLP-1 receptor agonists: a retrospective cohort study from the Global Collaborative Network: author list. J Endocrinol Invest. 2025, 48:483-97. 10.1007\/s40618-024-02466-4","journal-title":"J Endocrinol Invest"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.10333","article-title":"Roughly 12% of US adults have used a GLP-1 drug, even if unaffordable","volume":"332","author":"Harris E","year":"2024","unstructured":"Harris E. Roughly 12% of US adults have used a GLP-1 drug, even if unaffordable. JAMA. 2024, 332:8. 10.1001\/jama.2024.10333","journal-title":"JAMA"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2020.101102","article-title":"GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art","volume":"46","author":"Nauck MA","year":"2021","unstructured":"Nauck MA, Quast DR, Wefers J, Meier JJ. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Mol Metab. 2021, 46:101102. 10.1016\/j.molmet.2020.101102","journal-title":"Mol Metab"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.2298","article-title":"Nonalcoholic steatohepatitis: a review","volume":"323","author":"Sheka AC","year":"2020","unstructured":"Sheka AC, Adeyi O, Thompson J, Hameed B, Crawford PA, Ikramuddin S. Nonalcoholic steatohepatitis: a review. JAMA. 2020, 323:1175-83. 10.1001\/jama.2020.2298","journal-title":"JAMA"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2028395","article-title":"A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome PN","year":"2021","unstructured":"Newsome PN, Buchholtz K, Cusi K, et al.. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N Engl J Med. 2021, 384:1113-24. 10.1056\/NEJMoa2028395","journal-title":"N Engl J Med"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2021.07.010","article-title":"Glucagon-like peptide-1 receptor agonists and hepatic decompensation events in patients with cirrhosis and diabetes","volume":"20","author":"Simon TG","year":"2022","unstructured":"Simon TG, Patorno E, Schneeweiss S. Glucagon-like peptide-1 receptor agonists and hepatic decompensation events in patients with cirrhosis and diabetes. Clin Gastroenterol Hepatol. 2022, 20:1382-1393.e19. 10.1016\/j.cgh.2021.07.010","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso SP","year":"2016","unstructured":"Marso SP, Daniels GH, Brown-Frandsen K, et al.. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016, 375:311-22. 10.1056\/NEJMoa1603827","journal-title":"N Engl J Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/416465-impact-of-glucagon-like-peptide-1-agonists-on-hepatocellular-carcinoma-risk-and-management-in-type-2-diabetes-mellitus-a-scoping-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,28]],"date-time":"2025-12-28T15:56:12Z","timestamp":1766937372000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/416465-impact-of-glucagon-like-peptide-1-agonists-on-hepatocellular-carcinoma-risk-and-management-in-type-2-diabetes-mellitus-a-scoping-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,28]]},"references-count":32,"URL":"https:\/\/doi.org\/10.7759\/cureus.100252","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12,28]]}}}